Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy

被引:17
作者
Jessen, Christian [1 ]
Agerbaek, Mads [1 ]
Von Der Maase, Hans [1 ]
机构
[1] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus C, Denmark
关键词
ADVANCED BLADDER-CANCER; UROTHELIAL CANCER; GEMCITABINE; METHOTREXATE; COMBINATION; TUMORS; TRIAL; VINBLASTINE; DOXORUBICIN; PACLITAXEL;
D O I
10.1080/02841860802325932
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. The study was undertaken to identify pre-treatment clinical and histopathological factors of importance for response and survival after cisplatin-based combination chemotherapy, in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium. Patients and methods. Clinical, laboratory and histopathological data from 178 consecutive patients, representing all patients treated between 1991 and 2001 in a single institution, were collected. Correlations between these data and response and survival after chemotherapy were analysed using univariate and multivariate analyses. Results. Absence of visceral metastasis was the only parameter with independent correlation to the response to chemotherapy. Two of the analysed parameters were independently associated with increased survival: good performance status (PS1) and absence of visceral metastases. Stratification of the patient material according to number of these risk-factors present showed strong association with survival. Conclusion. It was possible to predict survival from pre-treatment clinical parameters and consequently it is possible to select groups with a high and low probability of obtaining long term survival following cisplatin-containing chemotherapy.
引用
收藏
页码:411 / 417
页数:7
相关论文
共 24 条
[11]   A systematic overview of chemotherapy effects in urothelial bladder cancer [J].
Nilsson, S ;
Ragnhammar, P ;
Glimelius, B ;
Nygren, P .
ACTA ONCOLOGICA, 2001, 40 (2-3) :371-390
[12]   A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence [J].
Ragnhammar, P ;
Brorsson, B ;
Nygren, P ;
Glimelius, B .
ACTA ONCOLOGICA, 2001, 40 (2-3) :391-411
[13]  
Roth BJ, 1996, SEMIN ONCOL, V23, P633
[14]   Metastatic urothelial cancer: Evaluation of prognostic factors and change in prognosis during the last twenty years [J].
Sengelov, L ;
Kamby, C ;
von der Maase, H .
EUROPEAN UROLOGY, 2001, 39 (06) :634-642
[15]  
SENGELOV L, 1995, CANCER, V76, P1797, DOI 10.1002/1097-0142(19951115)76:10<1797::AID-CNCR2820761018>3.0.CO
[16]  
2-W
[17]   Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer [J].
Sengelov, L ;
Kamby, C ;
Geertsen, F ;
Andersen, LJ ;
von der Maase, H .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (05) :357-364
[18]  
Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO
[19]  
2-9
[20]   Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer [J].
Stadler, WM ;
Hayden, A ;
von der Maase, H ;
Roychowdhury, D ;
Dogliotti, L ;
Seymour, L ;
Kaufmann, D ;
Moore, M .
UROLOGIC ONCOLOGY, 2002, 7 (04) :153-157